Literature DB >> 30430399

Vaccine strain Listeria monocytogenes bacteremia occurring 31 months after immunization.

Elias Fares1,2, Cindy B McCloskey3, Andres Gutierrez4, Michael Princiotta4, Linda J Salinas1, Douglas A Drevets5,6.   

Abstract

BACKGROUND: Listeria monocytogenes is a food-borne, facultative intracellular bacterium that causes severe diseases such as sepsis and meningoencephalitis in immunocompromised hosts. Because it stimulates robust T-lymphocyte-mediated responses, attenuated L. monocytogenes are candidate vaccine vectors for tumor immunotherapy. CASE: We report a case of bacteremia caused by vaccine strain L. monocytogenes (Axalimogene filolisbac) occurring 31 months after immunization against human papilloma virus (HPV) associated cervical cancer.
CONCLUSION: Receipt of a L. monocytogenes-based vaccine is a novel risk factor for delayed L. monocytogenes bacteremia.

Entities:  

Keywords:  Immunotherapy; Live vaccine; Recurrent listeriosis. Listeria vaccine

Mesh：

Substances：

Year:  2018        PMID： 30430399     DOI： 10.1007/s15010-018-1249-7

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   7.455


  16 in total

1.  Two cases of disseminated infection following live organism anti-cancer vaccine administration in cancer patients.

Authors:  James D Denham; Dae Hyun Lee; Manuel Castro; Shuchi Pandya; Sadaf Aslam; Sowmya Nanjappa; John N Greene
Journal:  Int J Infect Dis       Date:  2018-04-12       Impact factor: 3.623

Review 2.  Fracture healing: mechanisms and interventions.

Authors:  Thomas A Einhorn; Louis C Gerstenfeld
Journal:  Nat Rev Rheumatol       Date:  2014-09-30       Impact factor: 20.543

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.

Authors:  Caroline Charlier; Élodie Perrodeau; Alexandre Leclercq; Benoît Cazenave; Benoît Pilmis; Benoît Henry; Amanda Lopes; Mylène M Maury; Alexandra Moura; François Goffinet; Hélène Bracq Dieye; Pierre Thouvenot; Marie-Noëlle Ungeheuer; Mathieu Tourdjman; Véronique Goulet; Henriette de Valk; Olivier Lortholary; Philippe Ravaud; Marc Lecuit
Journal:  Lancet Infect Dis       Date:  2017-01-28       Impact factor: 25.071

5.  Relapsed infection due to Listeria monocytogenes confirmed by random amplified polymorphic DNA (RAPD) analysis.

Authors:  P N Levett; P Bennett; K O'Donaghue; K Bowker; D Reeves; A MacGowan
Journal:  J Infect       Date:  1993-09       Impact factor: 6.072

6.  Listeria monocytogenes virulence factors that stimulate endothelial cells.

Authors:  D A Drevets
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

Review 7.  Treatment failure and recurrent human listeriosis.

Authors:  J McLauchlin; A Audurier; A G Taylor
Journal:  J Antimicrob Chemother       Date:  1991-06       Impact factor: 5.790

Review 8.  Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.

Authors:  Laurence M Wood; Yvonne Paterson
Journal:  Front Cell Infect Microbiol       Date:  2014-05-12       Impact factor: 5.293

Review 9.  Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy.

Authors:  Brett A Miles; Bradley J Monk; Howard P Safran
Journal:  Gynecol Oncol Res Pract       Date:  2017-06-02

10.  Molecular evidence of Listeria monocytogenes infection relapse in a severe case of endocarditis.

Authors:  Giulia Ciceri; Maria Gori; Silvia Bianchi; Giovanni Corrado; Paolo Panisi; Angela Papa; Elisabetta Tanzi; Mirella Pontello
Journal:  JMM Case Rep       Date:  2017-09-18
View more
  8 in total

1.  A listeriolysin O subunit vaccine is protective against Listeria monocytogenes.

Authors:  Christopher C Phelps; Stephen Vadia; Prosper N Boyaka; Sanjay Varikuti; Zayed Attia; Purnima Dubey; Abhay R Satoskar; Rodney Tweten; Stephanie Seveau
Journal:  Vaccine       Date:  2020-07-17       Impact factor: 3.641

2.  First case of aorto-bi-iliac endograft thrombotic infection by Listeria monocytogenes: A case report.

Authors:  Enrico M Zardi; Nunzio Montelione; Vincenzo Catanese; Teresa Gabellini; Marco Caricato; Domenico M Zardi; Francesco Spinelli; Francesco Stilo
Journal:  Exp Ther Med       Date:  2022-06-06       Impact factor: 2.751

3.  Enhanced therapeutic efficacy of Listeria-based cancer vaccine with codon-optimized HPV16 E7.

Authors:  Feifei Duan; Jiaqi Chen; Hao Yao; Yuting Wang; Yanyan Jia; Zhiting Ling; Youwei Feng; Zhiming Pan; Yuelan Yin; Xin'An Jiao
Journal:  Hum Vaccin Immunother       Date:  2021-01-15       Impact factor: 3.452

4.  Safety evaluation of the canine osteosarcoma vaccine, live Listeria vector.

Authors:  Margaret L Musser; Erika P Berger; Chelsea D Tripp; Craig A Clifford; Philip J Bergman; Chad M Johannes
Journal:  Vet Comp Oncol       Date:  2020-08-17       Impact factor: 2.613

Review 5.  The Viable But Non-Culturable State of Listeria monocytogenes in the One-Health Continuum.

Authors:  Aurélie Lotoux; Eliane Milohanic; Hélène Bierne
Journal:  Front Cell Infect Microbiol       Date:  2022-03-18       Impact factor: 5.293

6.  Recombinant Listeria ivanovii strain expressing listeriolysin O in place of ivanolysin O might be a potential antigen carrier for vaccine construction.

Authors:  Qian Liang; Ruidan Li; Sijing Liu; Yunwen Zhang; Sicheng Tian; Qian Ou; Zhaobin Chen; Chuan Wang
Journal:  Front Microbiol       Date:  2022-07-22       Impact factor: 6.064

7.  Vaccine strain Listeria monocytogenes abscess in a dog: a case report.

Authors:  Margaret L Musser; Erika P Berger; Cameron Parsons; Sophia Kathariou; Chad M Johannes
Journal:  BMC Vet Res       Date:  2019-12-21       Impact factor: 2.741

Review 8.  Clinical Experience and Recent Advances in the Development of Listeria-Based Tumor Immunotherapies.

Authors:  Mariam Oladejo; Yvonne Paterson; Laurence M Wood
Journal:  Front Immunol       Date:  2021-04-14       Impact factor: 8.786
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.